Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer.

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Laryngeal Cancer.

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

In addition to Cabozantinib, Exelixis is developing zanzalintinib, a next-generation tyrosine kinase inhibitor. Analysts project that zanzalintinib could generate $5 billion in revenue by 2033, ...

The company's focus is now on its drug zanzalintinib, which is currently undergoing trials for colorectal cancer. However, BMO Capital Markets and BofA Securities have both downgraded Exelixis due ...

The focus now turns to Exelixis's drug zanzalintinib, a multi-kinase inhibitor currently undergoing trials for colorectal cancer (CRC). While the probability of success for zanzalintinib in CRC ...

The company's focus is now on its drug zanzalintinib, which is currently undergoing trials for colorectal cancer. However, BMO Capital Markets and BofA Securities have both downgraded Exelixis due to ...

Zanzalintinib stands out as Exelixis’ most clinically advanced asset with potential to become a primary contributor in the medium to long term, says the analyst, who is incorporating zanza into ...

Further, Exelixis is developing other cancer medicines. It is running several phase 3 studies for zanzalintinib, a product it hopes will follow in the footsteps of Cabometyx. Exelixis has several ...

Further, Exelixis is developing other cancer medicines. It is running several phase 3 studies for zanzalintinib, a product it hopes will follow in the footsteps of Cabometyx. Exelixis has several ...